Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
FDA Clears First Oral GLP-1 for Weight Loss On December 22, 2025, the FDA approved Novo Nordisks once-daily Wegovy pill (25 mg semaglutide), the first oral GLP-1 receptor agonist indicated for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight plus at least one weight-related comorbidity
Estruch R, Ros E, Salas-Salvad J, Covas MI, Corella D, Ars F, et al
Notably, GLP-1 and GIP/GLP-1 hybrid drugs are now clinically employed for diabetes and obesity, whereas GLP-2 drugs are used in the clinic to treat short bowel syndrome
However, clinical studies have shown that hypertension in T2D has no effect on cognition (Srikanth et al., 2020)
If you are dealing with constipation on tirzepatide that fiber supplements have not resolved, low potassium could be the underlying cause
If the scale isn't moving, your licensed provider can adjust your dose or switch your medication based on the progress you report on your refill forms and your check-ins
